Search Results

There are 66585 results for: content related to: Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib

  1. Bortezomib for the treatment of multiple myeloma

    Intervention Review

    The Cochrane Library

    Kathleen Scott, Patrick J Hayden, Andrea Will, Keith Wheatley and Imelda Coyne

    Published Online : 20 APR 2016, DOI: 10.1002/14651858.CD010816.pub2

  2. You have free access to this content
    Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 314–319, María Victoria Mateos, Paul G. Richardson, Meletios A. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu and Jesús F. San Miguel

    Version of Record online : 27 FEB 2015, DOI: 10.1002/ajh.23933

  3. You have free access to this content
    Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: E60–E65, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Despina Kalapanida, Constantinos Pamboucas, Elisavet Kaldara, Argyrios Ntalianis, Erasmia Psimenou, Savvas T. Toumanidis, Anna Tasidou, Evangelos Terpos and Meletios A. Dimopoulos

    Version of Record online : 9 MAR 2015, DOI: 10.1002/ajh.23936

  4. You have full text access to this OnlineOpen article
    Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

    European Journal of Haematology

    Volume 88, Issue 6, June 2012, Pages: 485–496, Martin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, Nina Gulbrandsen, Erik Holmberg, Per Trøllund Pedersen, Niels Frost Andersen, Björn Andréasson, Rolf Billström, Kristina Carlson, Margaretha S. Carlsson, Max Flogegård, Karin Forsberg, Peter Gimsing, Torbjörn Karlsson, Olle Linder, Hareth Nahi, Annika Othzén, Agneta Swedin and for the Nordic Myeloma Study Group (NMSG)

    Version of Record online : 30 MAR 2012, DOI: 10.1111/j.1600-0609.2012.01775.x

  5. You have free access to this content
    Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma


    Volume 118, Issue 22, 15 November 2012, Pages: 5560–5571, Bo Hui, Ying-Hong Shi, Zhen-Bin Ding, Jian Zhou, Cheng-Yu Gu, Yuan-Fei Peng, Hua Yang, Wei-Ren Liu, Guo-Ming Shi and Jia Fan

    Version of Record online : 19 APR 2012, DOI: 10.1002/cncr.27586

  6. Current status of new drugs for the treatment of patients with multiple myeloma

    Internal Medicine Journal

    Volume 36, Issue 12, December 2006, Pages: 781–789, M. Kenealy and 1 H. M. Prince 1,2

    Version of Record online : 9 NOV 2006, DOI: 10.1111/j.1445-5994.2006.01218.x

  7. Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

    Journal of Periodontal Research

    Volume 50, Issue 2, April 2015, Pages: 248–255, J. Kitagaki, S. Miyauchi, C. J Xie, M. Yamashita, S. Yamada, M. Kitamura and S. Murakami

    Version of Record online : 20 JUN 2014, DOI: 10.1111/jre.12202

  8. You have free access to this content
    Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

    BJU International

    Volume 109, Issue 8, April 2012, Pages: 1258–1268, Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo and Tomohiko Asano

    Version of Record online : 2 SEP 2011, DOI: 10.1111/j.1464-410X.2011.10533.x

  9. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials

    Hematological Oncology

    Volume 30, Issue 2, June 2012, Pages: 57–61, Lida Wang, Xuehong Ran, Baohong Wang, Zhixin Sheng and Liping Liu

    Version of Record online : 2 AUG 2011, DOI: 10.1002/hon.1007

  10. United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma

    International Journal of Laboratory Hematology

    Volume 36, Issue 6, December 2014, Pages: 665–675, N. Rabin, M. Lai, G. Pratt, G. Morgan, J. Snowden, J. Bird, G. Cook, S. Bowcock, R. Owen, K. Yong, A. Wechalaker, E. Low, F. Davies and On behalf ofthe United Kingdom Myeloma Forum

    Version of Record online : 27 MAR 2014, DOI: 10.1111/ijlh.12205

  11. You have full text access to this OnlineOpen article
    Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology

    Volume 171, Issue 3, November 2015, Pages: 344–354, Heinz Ludwig, Richard Greil, Tamas Masszi, Ivan Spicka, Ofer Shpilberg, Roman Hajek, Anna Dmoszynska, Bruno Paiva, María-Belén Vidriales, Graca Esteves, Anne Marie Stoppa, Don Robinson Jr, Shalini Chaturvedi, Ozlem Ataman, Christopher Enny, Huaibao Feng, Helgi van de Velde and Luisa Viterbo

    Version of Record online : 7 JUL 2015, DOI: 10.1111/bjh.13582

  12. You have free access to this content
    Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

    American Journal of Hematology

    Volume 84, Issue 10, October 2009, Pages: 657–660, Raman Sood, Harry Carloss, Robert Kerr, Jose Lopez, Martin Lee, Mark Druck, Ian B. Walters and Stephen J. Noga

    Version of Record online : 30 JUL 2009, DOI: 10.1002/ajh.21517

  13. You have full text access to this Open Access content
    Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1

    Cancer Science

    Volume 100, Issue 2, February 2009, Pages: 341–348, Masaki Ri, Shinsuke Iida, Takashi Ishida, Asahi Ito, Hiroki Yano, Atsushi Inagaki, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Atae Utsunomiya and Ryuzo Ueda

    Version of Record online : 5 DEC 2008, DOI: 10.1111/j.1349-7006.2008.01038.x

  14. You have free access to this content
    The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens


    Volume 117, Issue 9, 1 May 2011, Pages: 1884–1890, Giulia Benevolo, Alessandra Larocca, Massimo Gentile, Patrizia Pregno, Francesca Gay, Barbara Botto, Chiara Frairia, Andrea Evangelista, Fortunato Morabito, Mario Boccadoro, Umberto Vitolo and Antonio Palumbo

    Version of Record online : 18 NOV 2010, DOI: 10.1002/cncr.25743

  15. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

    Annals of the New York Academy of Sciences

    Volume 1274, Issue 1, December 2012, Pages: 48–59, Alejandro M. Gomez, Nick Willcox, Peter C. Molenaar, Wim Buurman, Pilar Martinez-Martinez, Marc H. De Baets and Mario Losen

    Version of Record online : 17 DEC 2012, DOI: 10.1111/j.1749-6632.2012.06824.x

  16. You have free access to this content
    Bendamustine in multiple myeloma

    European Journal of Haematology

    Volume 95, Issue 5, November 2015, Pages: 377–388, Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lucio Morabito, Francesco Mendicino, Giovanna Giagnuolo and Fortunato Morabito

    Version of Record online : 14 JUL 2015, DOI: 10.1111/ejh.12609

  17. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 118–133, Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico and Ian F. Pollack

    Version of Record online : 15 NOV 2011, DOI: 10.1002/mc.21835

  18. NFKB1 −94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

    British Journal of Haematology

    Volume 168, Issue 5, March 2015, Pages: 679–688, Gergely Varga, Gábor Mikala, Hajnalka Andrikovics, Magdalena Koszarska, Katalin Balassa, Emma Ádám, András Kozma, Attila Tordai and Tamás Masszi

    Version of Record online : 3 NOV 2014, DOI: 10.1111/bjh.13197

  19. You have free access to this content
    Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature


    Volume 110, Issue 5, 1 September 2007, Pages: 1042–1049, Ashraf Badros, Olga Goloubeva, Jay S. Dalal, Ilyas Can, Jennifer Thompson, Aaron P. Rapoport, Meyer Heyman, Gorgon Akpek and Robert G. Fenton

    Version of Record online : 25 JUL 2007, DOI: 10.1002/cncr.22921

  20. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

    Internal Medicine Journal

    Volume 45, Issue 1, January 2015, Pages: 94–105, H. Quach, D. Joshua, J. Ho, J. Szer, A. Spencer, S. J. Harrison, P. Mollee, A. W. Roberts, N. Horvath, D. Talulikar, B. To, A. Zannettino, R. Brown, L. Catley, B. Augustson, W. Jaksic, J. Gibson and H. M. Prince

    Version of Record online : 12 JAN 2015, DOI: 10.1111/imj.12640